Download PDF
Journal of Pediatric Epilepsy 2017; 06(01): 003-018
DOI: 10.1055/s-0036-1584935
Review Article
Georg Thieme Verlag KG Stuttgart · New York

The Effects of Antiepileptic Drugs on Pediatric Cognition, Mood, and Behavior

Khalid I. Afzal
1   Department of Psychiatry and Behavioral Neuroscience, The University of Chicago, Chicago, Illinois, United States
,
Seeba Anam
1   Department of Psychiatry and Behavioral Neuroscience, The University of Chicago, Chicago, Illinois, United States
,
Scott J. Hunter
1   Department of Psychiatry and Behavioral Neuroscience, The University of Chicago, Chicago, Illinois, United States
2   Department of Pediatrics, The University of Chicago, Chicago, Illinois, United States
› Author Affiliations
Further Information

Publication History

01 February 2015

21 March 2016

Publication Date:
01 July 2016 (online)

Also available at
   Permissions and Reprints

Abstract

In the past three decades, several new antiepileptic drugs (AEDs) have been marketed across the world, although with a surprisingly modest improvement in overall seizure control. During the same period, the use of AEDs as mood stabilizing or impulse control agents has been trending upwards, due to a notable increase in comorbid mood and behavior disorders in children, and a desire to address these pharmacologically. AEDs have been frequently associated with adverse mood and behavior changes, along with neuropsychiatric effects on attention, memory, and cognition. In this review, we discuss the use and adverse effects of the first- (e.g., barbiturates, carbamazepine, ethosuximide, phenytoin, valproate), second- (e.g., clobazam, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, stiripentol, vigabatrin, zonisamide), and third- (e.g., brivaracetam, eslicarbazepine acetate, lacosamide, perampanel, retigabine, rufinamide) generation AEDs in pediatric mood and behavior disorders. We also address what is currently known about the potential long-term neuropsychiatric consequences of AEDs. The distinction between the U.S. Food and Drug Administration-approved drugs versus off-label use of these drugs in the pediatric population is also examined.

Keywords

antiepileptic drugs - mood - behavior - cognition - adverse effects
 

  • References

  • 1 Wolf P. History of epilepsy: nosological concepts and classification. Epileptic Disord 2014; 16 (03) 261-269
    PubMedGoogle Scholar
  • 2 Chaudhary UJ, Duncan JS, Lemieux L. A dialogue with historical concepts of epilepsy from the Babylonians to Hughlings Jackson: persistent beliefs. Epilepsy Behav 2011; 21 (02) 109-114
    CrossrefPubMedGoogle Scholar
  • 3 Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 2010; 19 (10) 650-655
    CrossrefPubMedGoogle Scholar
  • 4 Clouston TS. Experiments to determine the precise effect of bromide of potassium in epilepsy. Br J Psychiatry 1868; 14 (67) 305-321
    CrossrefPubMedGoogle Scholar
  • 5 The Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013
    Google Scholar
  • 6 U.S. Food and Drug Administration (FDA). Available at: http://www.fda.gov/drugs/drugsafety/informationbydrugclass/default.htm . Accessed January 8, 2016
    PubMed
  • 7 Haymarket Media, Inc. Mood disorders. Available at: http://www.empr.com/mood-disorders/category/17/0/ . Accessed January 7, 2016
    PubMedGoogle Scholar
  • 8 Perucca P, Mula M. Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav 2013; 26 (03) 440-449
    CrossrefPubMedGoogle Scholar
  • 9 LaRoche SM. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007; 13 (03) 133-139
    CrossrefPubMedGoogle Scholar
  • 10 Potschka H. Pharmacological treatment strategies: Mechanisms of antiepileptic drugs. Epileptology 2013; 1 (01) 31-37
    CrossrefPubMedGoogle Scholar
  • 11 Brodie MJ, Covanis A, Gil-Nagel A. , et al. Antiepileptic drug therapy: does mechanism of action matter?. Epilepsy Behav 2011; 21 (04) 331-341
    CrossrefPubMedGoogle Scholar
  • 12 Afzal KI, Drossos T, Hunter S. Mood and behavior disorder in pediatric epilepsy-A review of literature. J Pediatr Epilepsy 2013; 2 (03) 157-172
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord 2014; 16 (04) 409-431
    CrossrefPubMedGoogle Scholar
  • 14 Tran AR, Zito JM, Safer DJ, Hundley SD. National trends in pediatric use of anticonvulsants. Psychiatr Serv 2012; 63 (11) 1095-1101
    CrossrefPubMedGoogle Scholar
  • 15 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000
    Google Scholar
  • 16 Italiano D, Capuano A, Alibrandi A. , et al. Indications of newer and older anti-epileptic drug use: findings from a southern Italian general practice setting from 2005-2011. Br J Clin Pharmacol 2015; 79 (06) 1010-1019
    CrossrefPubMedGoogle Scholar
  • 17 Drug safety update. Off-label or unlicensed use of medicines: prescribers' responsibilities. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087990 . Accessed January 24, 2016
    PubMedGoogle Scholar
  • 18 "Off-label" and investigational use of marketed drugs, biologics, and medical devices-information sheet. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/ucm126486.htm . Accessed March 14, 2016
    PubMedGoogle Scholar
  • 19 Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med 2008; 358 (14) 1427-1429
    CrossrefPubMedGoogle Scholar
  • 20 Wittich CM, Burkle CM, Lanier WL. Ten common questions (and their answers) about off-label drug use. Mayo Clin Proc 2012; 87 (10) 982-990
    CrossrefPubMedGoogle Scholar
  • 21 Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv 2009; 60 (09) 1175-1181
    CrossrefPubMedGoogle Scholar
  • 22 Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL. Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2008; 2 (01) 24 . Doi: 10.1186/1753-2000-2-24
    CrossrefPubMedGoogle Scholar
  • 23 Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004; 45 (09) 1141-1149
    CrossrefPubMedGoogle Scholar
  • 24 Findling RL, Ginsberg LD. The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. Neuropsychiatr Dis Treat 2014; 10: 1589-1597
    PubMedGoogle Scholar
  • 25 Schneider MR, Klein CC, Weber W. , et al. The effects of carbamazepine on prefrontal activation in manic youth with bipolar disorder. Psychiatry Res 2014; 223 (03) 268-270
    CrossrefPubMedGoogle Scholar
  • 26 Leucht S, Helfer B, Dold M, Kissling W, McGrath J. Carbamazepine for schizophrenia. Cochrane Database Syst Rev 2014; 5: CD001258 . Doi: 10.1002/14651858.CD001258.pub2
    PubMedGoogle Scholar
  • 27 Vajda FJ, Eadie MJ. The clinical pharmacology of traditional antiepileptic drugs. Epileptic Disord 2014; 16 (04) 395-408
    PubMedGoogle Scholar
  • 28 Bersudsky Y. Phenytoin: an anti-bipolar anticonvulsant?. Int J Neuropsychopharmacol 2006; 9 (04) 479-484
    CrossrefPubMedGoogle Scholar
  • 29 Gallagher P, Reid KS, Watson S. Phenytoin, an anti-bipolar anticonvulsant: a potential anti-glucocorticoid mechanism?. Int J Neuropsychopharmacol 2006; 9 (05) 627-628
    CrossrefPubMedGoogle Scholar
  • 30 Sitges M, Chiu LM, Reed RC. Effects of Levetiracetam, Carbamazepine, Phenytoin, Valproate, Lamotrigine, Oxcarbazepine, Topiramate, Vinpocetine and Sertraline on Presynaptic Hippocampal Na(+) and Ca(2+) Channels Permeability. Neurochem Res 2016; 41 (04) 758-769
    CrossrefPubMedGoogle Scholar
  • 31 Masuch A, Shieh CH, van Rooijen N, van Calker D, Biber K. Mechanism of microglia neuroprotection: Involvement of P2 × 7, TNFα, and valproic acid. Glia 2016; 64 (01) 76-89
    CrossrefPubMedGoogle Scholar
  • 32 Liu HY, Potter MP, Woodworth KY. , et al. Pharmacologic treatments for pediatric bipolar disorder: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2011; 50 (08) 749-762.e39
    CrossrefPubMedGoogle Scholar
  • 33 Pavuluri MN. Pharmacologic treatments for pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2011; 50 (12) 1290 , author reply 1290–1291. Doi: 10.1016/j.jaac.2011.09.002
    PubMedGoogle Scholar
  • 34 Pavuluri MN, Passarotti AM, Fitzgerald JM, Wegbreit E, Sweeney JA. Risperidone and divalproex differentially engage the fronto-striato-temporal circuitry in pediatric mania: a pharmacological functional magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry 2012; 51 (02) 157-170.e5
    CrossrefPubMedGoogle Scholar
  • 35 Padhy R, Saxena K, Remsing L, Huemer J, Plattner B, Steiner H. Symptomatic response to divalproex in subtypes of conduct disorder. Child Psychiatry Hum Dev 2011; 42 (05) 584-593
    CrossrefPubMedGoogle Scholar
  • 36 Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs 2012; 26 (03) 229-244
    CrossrefPubMedGoogle Scholar
  • 37 Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add-on therapy for refractory epilepsy. Cochrane Database Syst Rev 2014; 7: CD008295 . Doi: 10.1002/14651858.CD008295.pub3
    PubMedGoogle Scholar
  • 38 Reinares M, Rosa AR, Franco C. , et al. A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol 2013; 16 (02) 485-496
    CrossrefPubMedGoogle Scholar
  • 39 Bialer M. Chemical properties of antiepileptic drugs (AEDs). Adv Drug Deliv Rev 2012; 64 (10) 887-895
    CrossrefPubMedGoogle Scholar
  • 40 Fullerton CA, Busch AB, Frank RG. The rise and fall of gabapentin for bipolar disorder: a case study on off-label pharmaceutical diffusion. Med Care 2010; 48 (04) 372-379
    CrossrefPubMedGoogle Scholar
  • 41 Chace MJ, Zhang F, Fullerton CA, Huskamp HA, Gilden D, Soumerai SB. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder. J Clin Psychiatry 2012; 73 (11) 1388-1394
    CrossrefPubMedGoogle Scholar
  • 42 Schaffer LC, Schaffer CB, Miller AR, Manley JL, Piekut JA, Nordahl TE. An open trial of pregabalin as an acute and maintenance adjunctive treatment for outpatients with treatment resistant bipolar disorder. J Affect Disord 2013; 147 (01/03) 407-410
    CrossrefPubMedGoogle Scholar
  • 43 Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol 2003; 23 (05) 484-495
    CrossrefPubMedGoogle Scholar
  • 44 Peruzzolo TL, Tramontina S, Rohde LA, Zeni CP. Pharmacotherapy of bipolar disorder in children and adolescents: an update. Rev Bras Psiquiatr 2013; 35 (04) 393-405
    CrossrefPubMedGoogle Scholar
  • 45 Himmerich H, Bartsch S, Hamer H. , et al. Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro. J Psychiatr Res 2013; 47 (11) 1751-1759
    CrossrefPubMedGoogle Scholar
  • 46 Munkholm K, Braüner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res 2013; 47 (09) 1119-1133
    CrossrefPubMedGoogle Scholar
  • 47 Öncü B, Er O, Çolak B, Nutt DJ. Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series. J Psychopharmacol 2014; 28 (03) 282-283
    CrossrefPubMedGoogle Scholar
  • 48 Cerullo MA, Strakowski SM. A systematic review of the evidence for the treatment of acute depression in bipolar I disorder. CNS Spectr 2013; 18 (04) 199-208
    CrossrefPubMedGoogle Scholar
  • 49 Saricicek A, Maloney K, Muralidharan A. , et al. Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72 (06) 744-750
    CrossrefPubMedGoogle Scholar
  • 50 Ambrósio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002; 27 (01/02) 121-130
    CrossrefPubMedGoogle Scholar
  • 51 Macmillan CM, Gonzalez-Heydrich JM. Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents. Evid Based Ment Health 2007; 10 (02) 59 . Doi: 10.1136/ebmh.10.2.59
    CrossrefPubMedGoogle Scholar
  • 52 Wagner KD, Kowatch RA, Emslie GJ. , et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163 (07) 1179-1186
    CrossrefPubMedGoogle Scholar
  • 53 Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH. Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2011; (12) CD004857 . Doi: 10.1002/14651858.CD004857.pub2
    PubMedGoogle Scholar
  • 54 Angehagen M, Ben-Menachem E, Rönnbäck L, Hansson E. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochem Res 2003; 28 (02) 333-340
    CrossrefPubMedGoogle Scholar
  • 55 Hertzman M. Tiagabine for treatment of bipolar disorder with severe anxiety. Psychiatry (Edgmont) 2005; 2 (05) 11-11
    PubMedGoogle Scholar
  • 56 Vasudev A, Macritchie K, Rao SK, Geddes J, Young AH. Tiagabine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev 2012; 12: CD004694 . Doi: 10.1002/14651858.CD004694.pub3
    PubMedGoogle Scholar
  • 57 Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 2010; 12 (02) 116-141
    CrossrefPubMedGoogle Scholar
  • 58 Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2009; 19 (05) 539-545
    CrossrefPubMedGoogle Scholar
  • 59 Greenfield Jr LJ. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure 2013; 22 (08) 589-600
    CrossrefPubMedGoogle Scholar
  • 60 Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007; 30 (04) 230-240
    PubMedGoogle Scholar
  • 61 Haw C, Stubbs J. A survey of the off-label use of mood stabilizers in a large psychiatric hospital. J Psychopharmacol 2005; 19 (04) 402-407
    CrossrefPubMedGoogle Scholar
  • 62 Glauser TA. Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J Child Neurol 2004; 19 (Suppl. 01) S25-S38
    CrossrefPubMedGoogle Scholar
  • 63 Wolf SM, Carr A, Davis DC. , et al. The value of phenobarbital in the child who has had a single febrile seizure: a controlled prospective study. Pediatrics 1977; 59 (03) 378-385
    PubMedGoogle Scholar
  • 64 Knudsen FU, Vestermark S. Prophylactic diazepam or phenobarbitone in febrile convulsions: a prospective, controlled study. Arch Dis Child 1978; 53 (08) 660-663
    CrossrefPubMedGoogle Scholar
  • 65 Domizio S, Verrotti A, Ramenghi LA, Sabatino G, Morgese G. Anti-epileptic therapy and behaviour disturbances in children. Childs Nerv Syst 1993; 9 (05) 272-274
    CrossrefPubMedGoogle Scholar
  • 66 Herranz JL, Armijo JA, Arteaga R. Effectiveness and toxicity of phenobarbital, primidone, and sodium valproate in the prevention of febrile convulsions, controlled by plasma levels. Epilepsia 1984; 25 (01) 89-95
    CrossrefPubMedGoogle Scholar
  • 67 Vining EP, Mellitis ED, Dorsen MM. , et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80 (02) 165-174
    PubMedGoogle Scholar
  • 68 Brent DA, Crumrine PK, Varma R, Brown RV, Allan MJ. Phenobarbital treatment and major depressive disorder in children with epilepsy: a naturalistic follow-up. Pediatrics 1990; 85 (06) 1086-1091
    PubMedGoogle Scholar
  • 69 Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987; 80 (06) 909-917
    PubMedGoogle Scholar
  • 70 Pal DK. Phenobarbital for childhood epilepsy: systematic review. Paediatr Perinat Drug Ther 2006; 7 (01) 31-42
    CrossrefPubMedGoogle Scholar
  • 71 Banu SH, Jahan M, Koli UK, Ferdousi S, Khan NZ, Neville B. Side effects of phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial. BMJ 2007; 334 (7605): 1207 . Doi: 10.1136/bmj.39022.436389.BE
    CrossrefPubMedGoogle Scholar
  • 72 Herranz JL, Armijo JA, Arteaga R. Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 1988; 29 (06) 794-804
    CrossrefPubMedGoogle Scholar
  • 73 Thilothammal N, Banu K, Ratnam RS. Comparison of phenobarbitone, phenytoin with sodium valproate: randomized, double-blind study. Indian Pediatr 1996; 33 (07) 549-555
    PubMedGoogle Scholar
  • 74 de Silva M, MacArdle B, McGowan M. , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347 (9003): 709-713
    CrossrefPubMedGoogle Scholar
  • 75 Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 1987; 28 (Suppl. 03) S50-S58
    CrossrefPubMedGoogle Scholar
  • 76 Heller AJ, Chesterman P, Elwes RD. , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58 (01) 44-50
    CrossrefPubMedGoogle Scholar
  • 77 Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 1998; 39 (09) 952-959
    CrossrefPubMedGoogle Scholar
  • 78 McLellan DL, Swash M. Choreo-athetosis and encephalopathy induced by phenytoin. BMJ 1974; 2 (5912): 204-205
    CrossrefPubMedGoogle Scholar
  • 79 Chua HC, Venketasubramanian N, Tan CB, Tjia H. Paradoxical seizures in phenytoin toxicity. Singapore Med J 1999; 40 (04) 276-277
    PubMedGoogle Scholar
  • 80 Schmitz B. Psychiatric syndromes related to antiepileptic drugs. Epilepsia 1999; 40 (Suppl. 10) S65-S70
    CrossrefPubMedGoogle Scholar
  • 81 Marín LL, García-Peñas JJ, Herguedas JL. , et al. Phenytoin-induced visual disturbances mimicking Delirium Tremens in a child. Eur J Paediatr Neurol 2010; 14 (05) 460-463
    CrossrefPubMedGoogle Scholar
  • 82 Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R. ; CAPSS-027 Study Group. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003; 60 (09) 1483-1488
    CrossrefPubMedGoogle Scholar
  • 83 Sherard Jr ES, Steiman GS, Couri D. Treatment of childhood epilepsy with valproic acid: results of the first 100 patients in a 6-month trial. Neurology 1980; 30 (01) 31-35
    CrossrefPubMedGoogle Scholar
  • 84 Coulter DL, Wu H, Allen RJ. Valproic acid therapy in childhood epilepsy. JAMA 1980; 244 (08) 785-788
    CrossrefPubMedGoogle Scholar
  • 85 Berg I, Butler A, Ellis M, Foster J. Psychiatric aspects of epilepsy in childhood treated with carbamazepine, phenytoin or sodium valproate: a random trial. Dev Med Child Neurol 1993; 35 (02) 149-157
    PubMedGoogle Scholar
  • 86 Glauser TA, Cnaan A, Shinnar S. , et al; Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia 2013; 54 (01) 141-155
    CrossrefPubMedGoogle Scholar
  • 87 Marson AG, Al-Kharusi AM, Alwaidh M. , et al; SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369 (9566): 1016-1026
    CrossrefPubMedGoogle Scholar
  • 88 Silverstein FS, Parrish MA, Johnston MV. Adverse behavioral reactions in children treated with carbamazepine (Tegretol). J Pediatr 1982; 101 (05) 785-787
    CrossrefPubMedGoogle Scholar
  • 89 Kang HC, Eun BL, Lee CW. , et al; Korean Pediatric Topiramate Study Group. The effects on cognitive function and behavioral problems of topiramate compared to carbamazepine as monotherapy for children with benign rolandic epilepsy. Epilepsia 2007; 48 (09) 1716-1723
    CrossrefPubMedGoogle Scholar
  • 90 Kälviäinen R, Aikiä M, Saukkonen AM, Mervaala E, Riekkinen Sr PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995; 52 (10) 989-996
    CrossrefPubMedGoogle Scholar
  • 91 Zamponi N, Cardinali C. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 1999; 56 (05) 605-607
    CrossrefPubMedGoogle Scholar
  • 92 Chadwick D. ; Vigabatrin European Monotherapy Study Group. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 1999; 354 (9172): 13-19
    CrossrefPubMedGoogle Scholar
  • 93 Shehata GA, Bateh Ael-A, Hamed SA, Rageh TA, Elsorogy YB. Neuropsychological effects of antiepileptic drugs (carbamazepine versus valproate) in adult males with epilepsy. Neuropsychiatr Dis Treat 2009; 5: 527-533
    PubMedGoogle Scholar
  • 94 Lee SA, Lee HW, Heo K. , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure 2011; 20 (01) 49-54
    CrossrefPubMedGoogle Scholar
  • 95 Seidel WT, Mitchell WG. Cognitive and behavioral effects of carbamazepine in children: data from benign rolandic epilepsy. J Child Neurol 1999; 14 (11) 716-723
    CrossrefPubMedGoogle Scholar
  • 96 Glauser TA, Cnaan A, Shinnar S. , et al; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010; 362 (09) 790-799
    CrossrefPubMedGoogle Scholar
  • 97 Mandelbaum DE, Burack GD, Bhise VV. Impact of antiepileptic drugs on cognition, behavior, and motor skills in children with new-onset, idiopathic epilepsy. Epilepsy Behav 2009; 16 (02) 341-344
    CrossrefPubMedGoogle Scholar
  • 98 Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol 2013; 111: 707-718
    PubMedGoogle Scholar
  • 99 Wolf P. The clinical syndromes of forced normalisation. Folia Psychiatr Neurol Jpn 1984; 38: 187-192
    PubMedGoogle Scholar
  • 100 Chien J. Ethosuximide-induced mania in a 10-year-old boy. Epilepsy Behav 2011; 21 (04) 483-485
    CrossrefPubMedGoogle Scholar
  • 101 Bawden HN, Camfield CS, Camfield PR. , et al; Canadian Study Group for Childhood Epilepsy. The cognitive and behavioural effects of clobazam and standard monotherapy are comparable. Epilepsy Res 1999; 33 (02/03) 133-143
    CrossrefPubMedGoogle Scholar
  • 102 Sheth RD, Ronen GM, Goulden KJ, Penney S, Bodensteiner JB. Clobazam for intractable pediatric epilepsy. J Child Neurol 1995; 10 (03) 205-208
    CrossrefPubMedGoogle Scholar
  • 103 Sheth RD, Goulden KJ, Ronen GM. Aggression in children treated with clobazam for epilepsy. Clin Neuropharmacol 1994; 17 (04) 332-337
    CrossrefPubMedGoogle Scholar
  • 104 Chu-Shore CJ, Thiele EA. New drugs for pediatric epilepsy. Semin Pediatr Neurol 2010; 17 (04) 214-223
    CrossrefPubMedGoogle Scholar
  • 105 Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53 (05) (Suppl. 02) S53-S67
    PubMedGoogle Scholar
  • 106 Gay PE, Mecham GF, Coskey JS, Sadler T, Thompson JA. Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). Psychol Rep 1995; 77 (3 Pt 2): 1208-1210
    CrossrefPubMedGoogle Scholar
  • 107 Zupanc ML, Roell Werner R, Schwabe MS. , et al. Efficacy of felbamate in the treatment of intractable pediatric epilepsy. Pediatr Neurol 2010; 42 (06) 396-403
    CrossrefPubMedGoogle Scholar
  • 108 Theodore WH, Albert P, Stertz B. , et al. Felbamate monotherapy: implications for antiepileptic drug development. Epilepsia 1995; 36 (11) 1105-1110
    CrossrefPubMedGoogle Scholar
  • 109 Heyman E, Levin N, Lahat E, Epstein O, Gandelman-Marton R. Efficacy and safety of felbamate in children with refractory epilepsy. Eur J Paediatr Neurol 2014; 18 (06) 658-662
    CrossrefPubMedGoogle Scholar
  • 110 Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Res 2006; 71 (02/03) 89-101
    CrossrefPubMedGoogle Scholar
  • 111 Bourgeois BF. Felbamate. Semin Pediatr Neurol 1997; 4 (01) 3-8
    CrossrefPubMedGoogle Scholar
  • 112 Eddy CM, Rickards HE, Cavanna AE. Behavioral adverse effects of antiepileptic drugs in epilepsy. J Clin Psychopharmacol 2012; 32 (03) 362-375
    CrossrefPubMedGoogle Scholar
  • 113 Mikati MA, Choueri R, Khurana DS, Riviello J, Helmers S, Holmes G. Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. J Intellect Disabil Res 1998; 42 (Suppl. 01) 57-62
    PubMedGoogle Scholar
  • 114 Morris GL. Gabapentin. Epilepsia 1999; 40 (Suppl. 05) S63-S70
    CrossrefPubMedGoogle Scholar
  • 115 Lee DO, Steingard RJ, Cesena M, Helmers SL, Riviello JJ, Mikati MA. Behavioral side effects of gabapentin in children. Epilepsia 1996; 37 (01) 87-90
    PubMedGoogle Scholar
  • 116 Besag FM, Dulac O, Alving J, Mullens EL. Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizure 1997; 6 (01) 51-56
    CrossrefPubMedGoogle Scholar
  • 117 Eriksson AS, Nergårdh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998; 39 (05) 495-501
    CrossrefPubMedGoogle Scholar
  • 118 Cardenas JF, Rho JM, Ng YT. Reversible lamotrigine-induced neurobehavioral disturbances in children with epilepsy. J Child Neurol 2010; 25 (02) 182-187
    CrossrefPubMedGoogle Scholar
  • 119 McKee JR, Sunder TR, FineSmith R. , et al. Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. Epilepsy Behav 2003; 4 (04) 386-394
    CrossrefPubMedGoogle Scholar
  • 120 Marson AG, Al-Kharusi AM, Alwaidh M. , et al; SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369 (9566): 1000-1015
    CrossrefPubMedGoogle Scholar
  • 121 Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998; 39 (03) 280-282
    CrossrefPubMedGoogle Scholar
  • 122 Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000; 23 (02) 160-163
    CrossrefPubMedGoogle Scholar
  • 123 Vigneswari G, Sofiah A, Hussain IH. Lamotrigine as an add-on therapy in intractable paediatric epilepsy—the Kuala Lumpur Hospital experience. Med J Malaysia 2001; 56 (03) 359-364
    PubMedGoogle Scholar
  • 124 Brodbeck V, Jansen V, Fietzek U, Muehe C, Weber G, Heinen F. Long-term profile of lamotrigine in 119 children with epilepsy. Eur J Paediatr Neurol 2006; 10 (03) 135-141
    CrossrefPubMedGoogle Scholar
  • 125 Pressler RM, Binnie CD, Coleshill SG, Chorley GA, Robinson RO. Effect of lamotrigine on cognition in children with epilepsy. Neurology 2006; 66 (10) 1495-1499
    CrossrefPubMedGoogle Scholar
  • 126 Khurana DS, Kothare SV, Valencia I, Melvin JJ, Legido A. Levetiracetam monotherapy in children with epilepsy. Pediatr Neurol 2007; 36 (04) 227-230
    CrossrefPubMedGoogle Scholar
  • 127 Giroux PC, Salas-Prato M, Théorêt Y, Carmant L. Levetiracetam in children with refractory epilepsy: lack of correlation between plasma concentration and efficacy. Seizure 2009; 18 (08) 559-563
    CrossrefPubMedGoogle Scholar
  • 128 Krief P, Li Kan, Maytal J. Efficacy of levetiracetam in children with epilepsy younger than 2 years of age. J Child Neurol 2008; 23 (05) 582-584
    CrossrefPubMedGoogle Scholar
  • 129 Obeid M, Pong AW. Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy. Epilepsy Res 2010; 91 (01) 101-105
    CrossrefPubMedGoogle Scholar
  • 130 Peake D, Mordekar S, Gosalakkal J. , et al. Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Seizure 2007; 16 (02) 185-189
    CrossrefPubMedGoogle Scholar
  • 131 Callenbach PM, Arts WF, ten Houten R. , et al. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Eur J Paediatr Neurol 2008; 12 (04) 321-327
    CrossrefPubMedGoogle Scholar
  • 132 Fujikawa M, Kishimoto Y, Kakisaka Y. , et al. Obsessive-compulsive behavior induced by levetiracetam. J Child Neurol 2015; 30 (07) 942-944
    CrossrefPubMedGoogle Scholar
  • 133 Camacho A, Espín JC, Nuñez N, Simón R. Levetiracetam-induced reversible autistic regression. Pediatr Neurol 2012; 47 (01) 65-67
    CrossrefPubMedGoogle Scholar
  • 134 Perry MS, Benatar M. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review. Epilepsia 2007; 48 (06) 1123-1127
    CrossrefPubMedGoogle Scholar
  • 135 Helmstaedter C, Witt JA. The effects of levetiracetam on cognition: a non-interventional surveillance study. Epilepsy Behav 2008; 13 (04) 642-649
    CrossrefPubMedGoogle Scholar
  • 136 Ben-Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003; 12 (03) 131-135
    CrossrefPubMedGoogle Scholar
  • 137 Levisohn PM, Mintz M, Hunter SJ, Yang H, Jones J. ; N01103 Levetiracetam Study Group. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia 2009; 50 (11) 2377-2389
    CrossrefPubMedGoogle Scholar
  • 138 Lagae L, Buyse G, Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Seizure 2005; 14 (01) 66-71
    CrossrefPubMedGoogle Scholar
  • 139 de la Loge C, Hunter SJ, Schiemann J, Yang H. Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav 2010; 18 (03) 291-298
    CrossrefPubMedGoogle Scholar
  • 140 Piña-Garza JE, Espinoza R, Nordli D. , et al. Oxcarbazepine adjunctive therapy in infants and young children with partial seizures. Neurology 2005; 65 (09) 1370-1375
    CrossrefPubMedGoogle Scholar
  • 141 Kothare SV, Khurana DS, Mostofi N. , et al. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience. Pediatr Neurol 2006; 35 (04) 235-239
    CrossrefPubMedGoogle Scholar
  • 142 Seo JG, Lee DI, Hwang YH. , et al. Comparison of cognitive effects of lamotrigine and oxcarbazepine in epilepsy patients. J Clin Neurol 2007; 3 (01) 31-37
    CrossrefPubMedGoogle Scholar
  • 143 Eun SH, Eun BL, Lee JS. , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain Dev 2012; 34 (10) 818-823
    CrossrefPubMedGoogle Scholar
  • 144 Donati F, Gobbi G, Campistol J. , et al; Oxcarbazepine Cognitive Study Group. Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. Neurology 2006; 67 (04) 679-682
    CrossrefPubMedGoogle Scholar
  • 145 Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011; 52 (04) 826-836
    CrossrefPubMedGoogle Scholar
  • 146 Ciesielski AS, Samson S, Steinhoff BJ. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav 2006; 9 (03) 424-431
    CrossrefPubMedGoogle Scholar
  • 147 Chiron C, Marchand MC, Tran A. , et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000; 356 (9242): 1638-1642
    CrossrefPubMedGoogle Scholar
  • 148 Vossler DG, Morris III GL, Harden CL. , et al; Postmarketing Antiepileptic Drug Survey (PADS) group study investigators. Tiagabine in clinical practice: effects on seizure control and behavior. Epilepsy Behav 2013; 28 (02) 211-216
    CrossrefPubMedGoogle Scholar
  • 149 Pellock JM. Tiagabine (gabitril) experience in children. Epilepsia 2001; 42 (Suppl. 03) 49-51
    CrossrefPubMedGoogle Scholar
  • 150 Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995; 36 (Suppl. 06) S10-S13
    CrossrefPubMedGoogle Scholar
  • 151 Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39 (01) 33-42
    CrossrefPubMedGoogle Scholar
  • 152 Suppes T, Chisholm KA, Dhavale D. , et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 2002; 4 (05) 283-289
    CrossrefPubMedGoogle Scholar
  • 153 Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; 64 (10) 1245-1249
    CrossrefPubMedGoogle Scholar
  • 154 Kerr MP, Baker GA, Brodie MJ. A randomized, double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. Epilepsy Behav 2005; 7 (03) 472-480
    CrossrefPubMedGoogle Scholar
  • 155 Yeung S, Ferrie CD, Murdoch-Eaton DG, Livingston JH. Topiramate for drug-resistant epilepsies. Eur J Paediatr Neurol 2000; 4 (01) 31-33
    CrossrefPubMedGoogle Scholar
  • 156 Coppola G, Verrotti A, Resicato G. , et al. Topiramate in children and adolescents with epilepsy and mental retardation: a prospective study on behavior and cognitive effects. Epilepsy Behav 2008; 12 (02) 253-256
    CrossrefPubMedGoogle Scholar
  • 157 Moreland EC, Griesemer DA, Holden KR. Topiramate for intractable childhood epilepsy. Seizure 1999; 8 (01) 38-40
    CrossrefPubMedGoogle Scholar
  • 158 Martin P, Schreiner A, Rettig K, Schäuble B. Topiramate in patients with epilepsy and intellectual disability. Epilepsy Behav 2009; 14 (03) 496-502
    CrossrefPubMedGoogle Scholar
  • 159 Brandl U, Kurlemann G, Neubauer B, Rettig K, Schäuble B, Schreiner A. Seizure and cognitive outcomes in children and adolescents with epilepsy treated with topiramate. Neuropediatrics 2010; 41 (03) 113-120
    Article in Thieme ConnectPubMedGoogle Scholar
  • 160 Pandina GJ, Ness S, Polverejan E. , et al. Cognitive effects of topiramate in migraine patients aged 12 through 17 years. Pediatr Neurol 2010; 42 (03) 187-195
    CrossrefPubMedGoogle Scholar
  • 161 Witt JA, Elger CE, Helmstaedter C. Impaired verbal fluency under topiramate—evidence for synergistic negative effects of epilepsy, topiramate, and polytherapy. Eur J Neurol 2013; 20 (01) 130-137
    CrossrefPubMedGoogle Scholar
  • 162 Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia 2008; 49 (07) 1186-1191
    CrossrefPubMedGoogle Scholar
  • 163 Kluger G, Berz K, Holthausen H. The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy. Eur J Paediatr Neurol 2001; 5 (01) 37-40
    PubMedGoogle Scholar
  • 164 Ferrie CD, Robinson RO, Panayiotopoulos CP. Psychotic and severe behavioural reactions with vigabatrin: a review. Acta Neurol Scand 1996; 93 (01) 1-8
    PubMedGoogle Scholar
  • 165 Thomas L, Trimble M, Schmitz B, Ring H. Vigabatrin and behaviour disorders: a retrospective survey. Epilepsy Res 1996; 25 (01) 21-27
    CrossrefPubMedGoogle Scholar
  • 166 Wong IC. Retrospective study of vigabatrin and psychiatric behavioural disturbances. Epilepsy Res 1995; 21 (03) 227-230
    CrossrefPubMedGoogle Scholar
  • 167 Weber P, Dill P, Datta AN. Vigabatrin-induced forced normalization and psychosis—prolongated termination of behavioral symptoms but persistent antiepileptic effect after withdrawal. Epilepsy Behav 2012; 24 (01) 138-140
    CrossrefPubMedGoogle Scholar
  • 168 Guberman A, Bruni J. ; The Canadian Vigabatrin Study Group. Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. Seizure 2000; 9 (02) 112-118
    CrossrefPubMedGoogle Scholar
  • 169 Bhaumik S, Branford D, Duggirala C, Ismail IA. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure 1997; 6 (02) 127-133
    CrossrefPubMedGoogle Scholar
  • 170 Veggiotti P, De Agostini G, Muzio C. , et al. Vigabatrin use in psychotic epileptic patients: report of a prospective pilot study. Acta Neurol Scand 1999; 99 (03) 142-146
    CrossrefPubMedGoogle Scholar
  • 171 Gaily E, Appelqvist K, Kantola-Sorsa E. , et al. Cognitive deficits after cryptogenic infantile spasms with benign seizure evolution. Dev Med Child Neurol 1999; 41 (10) 660-664
    CrossrefPubMedGoogle Scholar
  • 172 White JR, Walczak TS, Marino SE, Beniak TE, Leppik IE, Birnbaum AK. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology 2010; 75 (06) 513-518
    CrossrefPubMedGoogle Scholar
  • 173 Kim HL, Aldridge J, Rho JM. Clinical experience with zonisamide monotherapy and adjunctive therapy in children with epilepsy at a tertiary care referral center. J Child Neurol 2005; 20 (03) 212-219
    CrossrefPubMedGoogle Scholar
  • 174 Faught E, Ayala R, Montouris GG, Leppik IE. ; Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57 (10) 1774-1779
    CrossrefPubMedGoogle Scholar
  • 175 Cavanna AE, Seri S. Psychiatric adverse effects of zonisamide in patients with epilepsy and mental disorder comorbidities. Epilepsy Behav 2013; 29 (02) 281-284
    CrossrefPubMedGoogle Scholar
  • 176 Thampratankul L, Khongkhatithum C, Visudtibhan A. Efficacy and safety of zonisamide in Thai children and adolescents with intractable seizures. J Child Neurol 2015; 30 (04) 527-531
    CrossrefPubMedGoogle Scholar
  • 177 Pack AM. Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial. Epilepsy Curr 2014; 14 (04) 196-198
    CrossrefPubMedGoogle Scholar
  • 178 UCB BIOSCIENCES, Inc. Brivaracetam safety and efficacy follow-up study in subjects with epilepsy (BRITE™). Available at: https://clinicaltrials.gov/ct2/show/NCT01339559 . Accessed March 14, 2016
    PubMedGoogle Scholar
  • 179 McCormack PL, Robinson DM. Eslicarbazepine acetate. CNS Drugs 2009; 23 (01) 71-79
    CrossrefPubMedGoogle Scholar
  • 180 Almeida L, Minciu I, Nunes T. , et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol 2008; 48 (08) 966-977
    CrossrefPubMedGoogle Scholar
  • 181 Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. ; 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007; 68 (15) 1197-1204
    CrossrefPubMedGoogle Scholar
  • 182 French JA, Abou-Khalil BW, Leroy RF. , et al; RESTORE 1/Study 301 Investigators. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011; 76 (18) 1555-1563
    CrossrefPubMedGoogle Scholar
  • 183 Chhim RF, Shelton CM, Christensen ML. Recent new drug approvals, part 2: drugs undergoing active clinical studies in children. J Pediatr Pharmacol Ther 2013; 18 (01) 14-38
    PubMedGoogle Scholar
  • 184 Pasha I, Kamate M, Didagi SK. Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy. Pediatr Neurol 2014; 51 (04) 509-514
    CrossrefPubMedGoogle Scholar
  • 185 Pasha I, Kamate M, Didagi SK. Reversible inattention and hyperactivity in a child on lacosamide - in south Indian subpopulation. IOSR. J Pharm Biol Sci. 2014; 9: 66-67
    PubMedGoogle Scholar
  • 186 Guilhoto LM, Loddenkemper T, Gooty VD. , et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2011; 44 (06) 414-419
    CrossrefPubMedGoogle Scholar
  • 187 Gavatha M, Ioannou I, Papavasiliou AS. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 2011; 20 (04) 691-693
    CrossrefPubMedGoogle Scholar
  • 188 Verrotti A, Loiacono G, Pizzolorusso A. , et al. Lacosamide in pediatric and adult patients: comparison of efficacy and safety. Seizure 2013; 22 (03) 210-216
    CrossrefPubMedGoogle Scholar
  • 189 Kim JS, Kim H, Lim BC. , et al. Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy. Brain Dev 2014; 36 (06) 510-515
    CrossrefPubMedGoogle Scholar
  • 190 Heyman E, Lahat E, Levin N, Berkovitch M, Gandelman-Marton R. Preliminary efficacy and safety of lacosamide in children with refractory epilepsy. Eur J Paediatr Neurol 2012; 16 (01) 15-19
    CrossrefPubMedGoogle Scholar
  • 191 Rastogi RG, Ng YT. Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study. J Child Neurol 2012; 27 (04) 492-495
    CrossrefPubMedGoogle Scholar
  • 192 Grosso S, Parisi P, Spalice A, Verrotti A, Balestri P. Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy. Eur J Paediatr Neurol 2014; 18 (01) 55-59
    CrossrefPubMedGoogle Scholar
  • 193 French JA, Krauss GL, Biton V. , et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012; 79 (06) 589-596
    CrossrefPubMedGoogle Scholar
  • 194 Steinhoff BJ, Ben-Menachem E, Ryvlin P. , et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013; 54 (08) 1481-1489
    CrossrefPubMedGoogle Scholar
  • 195 Krauss GL, Serratosa JM, Villanueva V. , et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012; 78 (18) 1408-1415
    CrossrefPubMedGoogle Scholar
  • 196 Wheless JW, Conry J, Krauss G, Mann A, LoPresti A, Narurkar M. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009; 24 (12) 1520-1525
    CrossrefPubMedGoogle Scholar
  • 197 Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70 (21) 1950-1958
    CrossrefPubMedGoogle Scholar
  • 198 Vendrame M, Loddenkemper T, Gooty VD. , et al. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol 2010; 43 (03) 155-158
    CrossrefPubMedGoogle Scholar
  • 199 Moavero R, Cusmai R, Specchio N. , et al. Rufinamide efficacy and safety as adjunctive treatment in children with focal drug resistant epilepsy: the first Italian prospective study. Epilepsy Res 2012; 102 (01/02) 94-99
    CrossrefPubMedGoogle Scholar
  • 200 Lee EH, Yum MS, Ko TS. Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea. Clin Neurol Neurosurg 2013; 115 (07) 926-929
    CrossrefPubMedGoogle Scholar
  • 201 Grosso S, Coppola G, Dontin SD. , et al. Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies. Eur J Paediatr Neurol 2014; 18 (05) 641-645
    CrossrefPubMedGoogle Scholar
  • 202 Kaufman KR, Struck PJ. Activation of suicidal ideation with adjunctive rufinamide in bipolar disorder. Epilepsy Behav 2011; 20 (02) 386-389
    CrossrefPubMedGoogle Scholar
  • 203 Cusmai R, Verrotti A, Moavero R. , et al. Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders. Epilepsy Res 2014; 108 (03) 542-546
    CrossrefPubMedGoogle Scholar
  • 204 Johannessen SI, Landmark CJ. Value of therapeutic drug monitoring in epilepsy. Expert Rev Neurother 2008; 8 (06) 929-939
    CrossrefPubMedGoogle Scholar
  • 205 Mula M, Sander JW. Suicide risk in people with epilepsy taking antiepileptic drugs. Bipolar Disord 2013; 15 (05) 622-627
    CrossrefPubMedGoogle Scholar
  • 206 Fountoulakis KN, Gonda X, Baghai TC. , et al. Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. Int J Psychiatry Clin Pract 2015; 19 (03) 158-167
    CrossrefPubMedGoogle Scholar
  • 207 Machado RA, Espinosa AG, Melendrez D, González YR, García VF, Rodríguez YQ. Suicidal risk and suicide attempts in people treated with antiepileptic drugs for epilepsy. Seizure 2011; 20 (04) 280-284
    CrossrefPubMedGoogle Scholar
  • 208 Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010; 75 (04) 335-340
    CrossrefPubMedGoogle Scholar
  • 209 Jones JE, Siddarth P, Gurbani S, Shields WD, Caplan R. Screening for suicidal ideation in children with epilepsy. Epilepsy Behav 2013; 29 (03) 521-526
    CrossrefPubMedGoogle Scholar
  • 210 Caplan R, Siddarth P, Gurbani S, Hanson R, Sankar R, Shields WD. Depression and anxiety disorders in pediatric epilepsy. Epilepsia 2005; 46 (05) 720-730
    CrossrefPubMedGoogle Scholar